Dry and Wet Age-Related Macular Degeneration – Special Topics – Special Topics: Gene Therapies in Ophthalmology (US)
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo, Biogen’s Byooviz, Coherus’s Cimerli, and Novartis’s Beovu. Although IVT agents drive favorable outcomes for most patients, they require chronic injections that limit persistency and compliance and prevent long-term achievement of an optimal response. Gene therapy for wet AMD is on the horizon, bringing the potential to reduce IVT injections and improve outcomes for patients, although questions remain about the profiles of the most eligible candidates for these innovative therapeutic options. The market for IVT therapies to treat advanced dry AMD with geographic atrophy (GA) is far less developed, but gene therapy is also advancing in the pipeline. This report addresses key questions regarding ophthalmologists’ willingness to prescribe emerging gene therapies in both forms of AMD and key drivers of their prescribing, their preferences regarding differentiating clinical attributes, and through conjoint analysis, the clinical attributes they prioritize when selecting optimal wet AMD gene therapy candidates.
Questions answered
- What percentage of wet AMD or GA patients are treated with key IVT agents? What percentage show a meaningful positive response?
- On average, how many injections per year do patients receive with key current therapies? What percentage of patients want a lower injection frequency than they can currently achieve?
- Where do ophthalmologists rank IVT, subretinal, and suprachoroidal gene therapy delivery among potential achievements for future wet AMD therapies?
- Based on available information, how willing are U.S. ophthalmologists to prescribe emerging gene therapies to their wet AMD or GA patients? What percentage of patients are candidates for these treatments?
- Which wet AMD patients are most likely to receive a gene therapy? How does a patient’s status on their current IVT treatment—including visual acuity, anatomical response, injection frequency, adverse events, eye treatment status, and age—influence their likelihood to be prescribed a gene therapy?
Content highlights
Geography: United States
Primary Research: Survey of 101 U.S. ophthalmologists / retinal specialists in October 2023
Key agents covered: ABBV-RGX-314, ixo-vec (ADVM-022), 4D-150, JNJ-1887 (HMR59)
Product description
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report on gene therapies in ophthalmology will help drug marketers and developers gain needed insight into treatment dynamics for IVT options in wet AMD and GA, HCPs’ desired achievements for emerging therapies, and physicians’ willingness to prescribe key emerging gene therapies; it also provides a conjoint analysis of clinical attributes that render a wet AMD patient to be an optimal candidate to receive a future gene therapy.
Saadiq Hasan, M.P.H., Healthcare Research & Data Analyst, CNS and Ophthalmology. Mr. Hasan covers the neurology space, specializing in Parkinson’s disease. He conducts extensive primary and secondary market research and analysis of the treatment of Parkinson’s disease, as well as other neurologic diseases. Prior to joining Clarivate, Mr. Hasan earned his Master of Public Health degree from the University of Virginia.
John Crowley, Ph.D., is the principal director of the Infectious, Niche, & Rare Diseases team at DRG, part of Clarivate. Prior to his current role, he was a director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. Dr. Crowley holds a Ph.D. from the University of Massachusetts Medical School and a bachelor’s degree from Worcester Polytechnic Institute.